SCHEMBL4848593

SCHEMBL4848593

Cc1cc(O)cc(CO)c1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.67
ALDH1A1 P00352 1/20 0.57
HCAR1 Q9BXC0 1/20 0.46
PTGS2 P35354 3/20 0.37
PGK1 P00558 1/20 0.37
PGK2 P07205 1/20 0.37
CYP3A4 P08684 1/20 0.37
SELL P14151 1/20 0.36
SELP P16109 1/20 0.36
SELE P16581 1/20 0.36
KDM4E B2RXH2 1/20 0.35
CASP6 P55212 1/20 0.35
LTA4H P09960 1/20 0.34
HSP90AB1 P08238 1/20 0.34
SHBG P04278 1/20 0.34
HSD17B1 P14061 1/20 0.34
HSD17B2 P37059 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31139273 1.00 ACHE (0.67) ACHEALDH1A1HCAR1PTGS2PGK1
SCHEMBL92965 0.84 ACHE (0.48) ACHEALDH1A1PGK1PGK2SELL
SCHEMBL501769 0.84 PGK1 (0.48) ACHEALDH1A1PGK1PGK2SELL
SCHEMBL10536338 0.83 ESR1 (0.53) ACHEALDH1A1HCAR1HSD17B1HSD17B2
SCHEMBL18458343 0.83 ALDH1A1 (0.55) ACHEALDH1A1HCAR1PTGS2PGK1
SCHEMBL29215628 0.82 ALDH1A1 (0.60) ACHEALDH1A1HCAR1PTGS2PGK1
SCHEMBL30899188 0.82 ALDH1A1 (0.60) ACHEALDH1A1HCAR1PTGS2PGK1
SCHEMBL351788 0.81 ACHE (0.88) ACHEPTGS2CYP3A4KDM4ECASP6
SCHEMBL248195 0.81 ACHE (1.00) ACHEALDH1A1PTGS2CYP3A4KDM4E
SCHEMBL31200644 0.80 ALDH1A1 (0.57) ACHEALDH1A1HCAR1PTGS2PGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170342047-A1 Cancerous Cell Growth Inhibiting Compounds WISYS TECHNOLOGY FOUNDATION, INC. 2017-11-30 US disclosed
US-9682953-B2 Amide compounds, compositions and applications thereof ADVINUS THERAPEUTICS LIMITED (IN) 2017-06-20 US disclosed
US-9682953-B2 Amide compounds, compositions and applications thereof ADVINUS THERAPEUTICS LIMITED (IN) 2017-06-20 US disclosed
US-9682953-B2 Amide compounds, compositions and applications thereof ADVINUS THERAPEUTICS LIMITED (IN) 2017-06-20 US disclosed
CN-103958473-B Amide compound, composition and application thereof ADVINUS THERAPEUTICS LTD. (IN) 2016-11-30 CN disclosed
US-20150065464-A1 AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF ADVINUS THERAPEUTICS LIMITED (IN) 2015-03-05 US disclosed
US-8945508-B2 Dendrimer compositions and methods of synthesis THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-02-03 US disclosed
EP-2758375-A1 AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF Advinus Therapeutics Limited (IN) 2014-07-30 EP disclosed
CN-103958473-A Amide compound, composition and application thereof ADVINUS THERAPEUTICS LTD 2014-07-30 CN disclosed
WO-2013042139-A1 AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF ADVINUS THERAPEUTICS LIMITED (IN) 2013-03-28 WO disclosed
US-RE40558-E1 Therapeutic uses of di-aryl acid derivatives SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-28 US disclosed
US-7429669-B2 Therapeutic compounds ALLERGAN, INC. (US) 2008-09-30 US disclosed
US-20070293669-A1 Invertible amphiphilic polymers UNIVERSITY OF MASSACHUSETTS 2007-12-20 US disclosed
CN-101070316-A Diaryl acid derivatives as PPAR receptor ligands AVENTIS PHARMA GMBH (DE) 2007-11-14 CN disclosed
CN-1331862-C Diaryl acid derivatives as PPAR receptor ligands AVENTIS PHARAMCEUTICALS PRODUC (DE) 2007-08-15 CN disclosed
US-6635655-B1 Agonists or antagonists of peroxisome proliferator-activated receptors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-10-21 US disclosed
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed
WO-1989004305-A1 QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 RORER INTERNATIONAL (OVERSEAS) INC. (US) 1989-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342047-A1 Cancerous Cell Growth Inhibiting Compounds TYR, MKI67, MC1R ACHE 3485/4885ALDH1A1 113/4885HCAR1 1654/4885
US-20070293669-A1 Invertible amphiphilic polymers PHOSPHO1, INF2, AQP1 ACHE 1807/4885ALDH1A1 4784/4885HCAR1 3298/4885
US-20150065464-A1 AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF FAAH, FAAH2, TPH1 ACHE 9/4885ALDH1A1 2023/4885HCAR1 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.